In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli.

Antimicrobial Agents and Chemotherapy
M A Buesing, J H Jorgensen

Abstract

The in vitro synergistic activity of aztreonam in combination with piperacillin, moxalactam, cefotaxime, cefoperazone, and amikacin was examined against multiply resistant isolates of the family Enterobacteriaceae and Pseudomonas aeruginosa. Aztreonam in combination with amikacin demonstrated synergy against 71% of the isolates, whereas combinations of aztreonam plus a second beta-lactam demonstrated synergy against 42% of the isolates.

References

Mar 1, 1977·The American Journal of the Medical Sciences·J KlasterskyJ M Prevost
Jan 1, 1978·Chemotherapy·E T AndersonW L Hewitt
Dec 1, 1981·The Journal of Antimicrobial Chemotherapy·D M Livermore, J D Williams
Dec 1, 1981·The Journal of Antimicrobial Chemotherapy·R WiseJ Hancox
Jan 1, 1982·Antimicrobial Agents and Chemotherapy·R B SykesN H Georgopapadakou

❮ Previous
Next ❯

Citations

Dec 25, 2003·Burns : Journal of the International Society for Burn Injuries·Edward E TredgetSarvesh Logsetty
Aug 1, 1997·Journal of the American Academy of Dermatology·M E EpsteinN S Sadick
Jun 1, 1986·Antimicrobial Agents and Chemotherapy·R E CondonB Levinson
Jun 22, 1990·Pharmaceutisch Weekblad. Scientific Edition·R VanhoofM L Couvreur
Dec 5, 2008·Expert Review of Anti-infective Therapy·Mohan P Venkatesh, Joseph A Garcia-Prats
Nov 1, 1991·Mayo Clinic Proceedings·N S Brewer, W C Hellinger
Apr 30, 1999·Mayo Clinic Proceedings·W C Hellinger, N S Brewer
Jul 15, 1985·The American Journal of Medicine·A L Baltch, R P Smith
Aug 1, 1986·The American Journal of Medicine·P G JonesG P Bodey
Jan 13, 2001·Dermatologic Clinics·N S Sadick
Oct 14, 2014·Diagnostic Microbiology and Infectious Disease·Christine RahmeThomas P Lodise
Jan 1, 1986·Scandinavian Journal of Infectious Diseases·S BengtssonL Nilsson
Feb 25, 1988·The New England Journal of Medicine·G R Donowitz, G L Mandell
Jul 1, 1986·Pharmacotherapy·S J Childs, G P Bodey
Sep 1, 1991·DICP : the Annals of Pharmacotherapy·A W Hopefl
Jul 29, 2021·ELife·Aditi BatraHinrich Schulenburg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.